Our 3D multi-omics platform is generating unparalleled genetic validation of disease-relevant targets across the entire human genome, in the most relevant cell types – to more than double the probability of success
About us
We are the only biotechnology therapeutics discovery and development company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.
Unlocking decades worth of genetic data and providing unparalleled validation via our proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, we are able to expedite drug discovery and precision medicine.
Our 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. This approach supports both target prioritization, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible. It also allows the stratification of patients into responder groups to improve and accelerate clinical trials.
We have an active in-house target discovery and development program, focusing on common diseases with large unmet needs, with an initial focus on autoimmune indications. We also welcome enquiries from potential partners looking to enable and accelerate their discovery and development initiatives.
Enhanced Genomics was spun out from the laboratories of Dr. Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organization of the genome at the Babraham Institute in Cambridge, UK.
Investors
Thank you to our investors: BGF, Bioqube Ventures, Meltwind Advisors, Parkwalk, Start Codon, and our private investors for their support.
